Mursla Bio

Executive Summary

Mursla Bio is a UK-based precision diagnostics company pioneering the analysis of organ-specific extracellular vesicles (EVs) from blood using its proprietary AI platform. The company’s lead product, EvoLiver, is a non-invasive blood test designed to detect liver cancer early in high-risk patients with cirrhosis. By isolating and analyzing EVs released specifically from the liver, EvoLiver aims to address the critical unmet need for sensitive, earlier detection of hepatocellular carcinoma (HCC), improving survival rates and reducing healthcare costs. Mursla’s AI-driven approach integrates multi-omics data from EVs to identify disease-specific signatures, potentially enabling greater accuracy than traditional biomarkers. Founded in 2018 and based in Cambridge, the company has built a hepatology-focused pipeline and is positioned to expand into other organ-specific indications. With a strong scientific foundation and a clear clinical pathway, Mursla Bio represents a compelling opportunity in the liquid biopsy space, though it remains at a relatively early stage without disclosed funding rounds or commercial products.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation for EvoLiver40% success
• Q4 2026Pivotal Clinical Study Results for EvoLiver in Cirrhosis Patients50% success
• Q1 2027Strategic Partnership with Major Pharma for HCC Screening35% success